Experimental brain cancer vaccine made available to patients with no other options
NCT ID NCT04802447
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This program gives certain glioblastoma patients access to SurVaxM, a drug that helps the immune system fight brain cancer. It is for patients who cannot join other trials or who have already benefited from SurVaxM in a previous study. The treatment involves four doses given two weeks apart, followed by a dose every three months for up to two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SurVaxM (a vaccine-like drug that trains the immune system to attack cancer cells)
- What this could lead to
- If it works, this could offer a way to extend survival for people with glioblastoma who have few other options.
- What could go wrong
- This is an expanded access program, not a formal trial, so results are not proven. The drug may not work for everyone and requires repeated doses.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?
- A simple lotion duo may shield skin from Tumor-Treating fields
- Can a One-Two punch slow recurrent brain cancer?